Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
( 26 27 26 27 I-clinical_variable
ANC 27 30 27 30 I-clinical_variable
) 30 31 30 31 I-clinical_variable
≥1.5 32 36 32 36 O
x 37 38 37 38 I-lower_bound
10 39 41 39 41 I-lower_bound
^ 41 42 41 42 I-lower_bound
9 42 43 42 43 I-lower_bound
/ 43 44 43 44 I-lower_bound
L 44 45 44 45 I-lower_bound
, 45 46 45 46 O
hemoglobin 47 57 47 57 B-clinical_variable
( 58 59 58 59 I-clinical_variable
Hgb 59 62 59 62 I-clinical_variable
) 62 63 62 63 I-clinical_variable
> 64 65 64 65 O
9 65 66 65 66 B-lower_bound
g 67 68 67 68 I-lower_bound
/ 68 69 68 69 I-lower_bound
dL 69 71 69 71 I-lower_bound
, 71 72 71 72 O
and 73 76 73 76 O
platelet 77 85 77 85 B-clinical_variable
count 86 91 86 91 I-clinical_variable
≥100 92 96 92 96 O
X 97 98 97 98 I-lower_bound
10 99 101 99 101 I-lower_bound
^ 101 102 101 102 I-lower_bound
9 102 103 102 103 I-lower_bound
/ 103 104 103 104 I-lower_bound
L 104 105 104 105 I-lower_bound

Active 0 6 106 112 O
secondary 7 16 113 122 O
malignancy 17 27 123 133 B-cancer
unless 28 34 134 140 O
the 35 38 141 144 O
malignancy 39 49 145 155 O
is 50 52 156 158 O
not 53 56 159 162 O
expected 57 65 163 171 O
to 66 68 172 174 O
interfere 69 78 175 184 O
with 79 83 185 189 O
the 84 87 190 193 O
evaluation 88 98 194 204 O
of 99 101 205 207 O
safety 102 108 208 214 O
and 109 112 215 218 O
is 113 115 219 221 O
approved 116 124 222 230 O
by 125 127 231 233 O
the 128 131 234 237 O
Sponsor 132 139 238 245 O

Age 0 3 246 249 B-age
greater 4 11 250 257 O
or 12 14 258 260 O
equal 15 20 261 266 O
to 21 23 267 269 O
18 24 26 270 272 B-lower_bound
years 27 32 273 278 I-lower_bound

Agree 0 5 279 284 O
to 6 8 285 287 O
pre 9 12 288 291 B-treatment
and 13 16 292 295 I-treatment
post 17 21 296 300 I-treatment
- 21 22 300 301 I-treatment
treatment 22 31 301 310 I-treatment
tumor 32 37 311 316 I-treatment
biopsies 38 46 317 325 I-treatment

Albumin 0 7 326 333 B-clinical_variable
≥ 8 9 334 335 O
3.0g 10 14 336 340 B-lower_bound
/ 14 15 340 341 I-lower_bound
dL 15 17 341 343 I-lower_bound

Allowable 0 9 344 353 O
prior 10 15 354 359 B-treatment
therapy 16 23 360 367 I-treatment

Any 0 3 368 371 O
patients 4 12 372 380 O
on 13 15 381 383 O
warfarin 16 24 384 392 B-treatment
therapy 25 32 393 400 I-treatment

As 0 2 401 403 O
bone 3 7 404 408 O
marrow 8 14 409 415 O
suppression 15 26 416 427 O
including 27 36 428 437 O
anemia 37 43 438 444 B-chronic_disease
, 43 44 444 445 O
neutropenia 45 56 446 457 B-chronic_disease
, 56 57 457 458 O
and 58 61 459 462 O
thrombocytopenia 62 78 463 479 B-chronic_disease
have 79 83 480 484 O
been 84 88 485 489 O
reported 89 97 490 498 O
in 98 100 499 501 O
patients 101 109 502 510 O
receiving 110 119 511 520 O
sirolimus 120 129 521 530 B-treatment
monotherapy 130 141 531 542 I-treatment
, 141 142 542 543 O
these 143 148 544 549 O
adverse 149 156 550 557 O
effects 157 164 558 565 O
may 165 168 566 569 O
be 169 171 570 572 O
exacerbated 172 183 573 584 O
in 184 186 585 587 O
combination 187 198 588 599 O
with 199 203 600 604 O
PLX3397 204 211 605 612 B-treatment
for 212 215 613 616 O
which 216 221 617 622 O
patients 222 230 623 631 O
will 231 235 632 636 O
be 236 238 637 639 O
closely 239 246 640 647 O
monitored 247 256 648 657 O

Aspartate 0 9 658 667 B-clinical_variable
aminotransferase 10 26 668 684 I-clinical_variable
( 27 28 685 686 I-clinical_variable
AST)/alanine 28 40 686 698 I-clinical_variable
aminotransferase 41 57 699 715 I-clinical_variable
( 58 59 716 717 I-clinical_variable
ALT 59 62 717 720 I-clinical_variable
) 62 63 720 721 I-clinical_variable
≤ 64 65 722 723 O
upper 66 71 724 729 O
limit 72 77 730 735 O
of 78 80 736 738 O
normal 81 87 739 745 O
( 88 89 746 747 O
ULN 89 92 747 750 O
) 92 93 750 751 O
or 94 96 752 754 O
< 97 98 755 756 O
2.5 99 102 757 760 B-upper_bound
x 103 104 761 762 I-upper_bound
ULN 105 108 763 766 I-upper_bound
in 109 111 767 769 O
the 112 115 770 773 O
presence 116 124 774 782 O
of 125 127 783 785 O
liver 128 133 786 791 B-cancer
metastases 134 144 792 802 I-cancer

Because 0 7 803 810 O
no 8 10 811 813 O
dosing 11 17 814 820 O
or 18 20 821 823 O
adverse 21 28 824 831 O
event 29 34 832 837 O
data 35 39 838 842 O
are 40 43 843 846 O
currently 44 53 847 856 O
available 54 63 857 866 O
on 64 66 867 869 O
the 67 70 870 873 O
use 71 74 874 877 O
of 75 77 878 880 O
PLX3397 78 85 881 888 O
in 86 88 889 891 O
combination 89 100 892 903 O
with 101 105 904 908 O
sirolimus 106 115 909 918 O
in 116 118 919 921 O
patients 119 127 922 930 O
< 128 129 931 932 O
18 129 131 932 934 B-upper_bound
years 132 137 935 940 I-upper_bound
of 138 140 941 943 O
age 141 144 944 947 B-age
, 144 145 947 948 O
children 146 154 949 957 O
are 155 158 958 961 O
excluded 159 167 962 970 O
from 168 172 971 975 O
this 173 177 976 980 O
study 178 183 981 986 O
, 183 184 986 987 O
but 185 188 988 991 O
will 189 193 992 996 O
be 194 196 997 999 O
eligible 197 205 1000 1008 O
for 206 209 1009 1012 O
future 210 216 1013 1019 O
pediatric 217 226 1020 1029 O
trials 227 233 1030 1036 O

Because 0 7 1037 1044 O
there 8 13 1045 1050 O
is 14 16 1051 1053 O
an 17 19 1054 1056 O
unknown 20 27 1057 1064 O
but 28 31 1065 1068 O
potential 32 41 1069 1078 O
risk 42 46 1079 1083 O
for 47 50 1084 1087 O
adverse 51 58 1088 1095 O
events 59 65 1096 1102 O
in 66 68 1103 1105 O
nursing 69 76 1106 1113 O
infants 77 84 1114 1121 O
secondary 85 94 1122 1131 O
to 95 97 1132 1134 O
treatment 98 107 1135 1144 O
of 108 110 1145 1147 O
the 111 114 1148 1151 O
mother 115 121 1152 1158 O
with 122 126 1159 1163 O
PLX3397 127 134 1164 1171 B-treatment
and 135 138 1172 1175 O
sirolimus 139 148 1176 1185 B-treatment
, 148 149 1185 1186 O
breastfeeding 150 163 1187 1200 O
should 164 170 1201 1207 O
be 171 173 1208 1210 O
discontinued 174 186 1211 1223 O
if 187 189 1224 1226 O
the 190 193 1227 1230 O
mother 194 200 1231 1237 O
is 201 203 1238 1240 O
treated 204 211 1241 1248 O
with 212 216 1249 1253 O
PLX3397 217 224 1254 1261 O
and 225 228 1262 1265 O
sirolimus 229 238 1266 1275 O

Bilirubin 0 9 1276 1285 B-clinical_variable
≤ 10 11 1286 1287 O
ULN 12 15 1288 1291 B-clinical_variable
; 15 16 1291 1292 O
patients 17 25 1293 1301 O
with 26 30 1302 1306 O
hyperbilirubinemia 31 49 1307 1325 O
clinically 50 60 1326 1336 O
consistent 61 71 1337 1347 O
with 72 76 1348 1352 O
an 77 79 1353 1355 O
inherited 80 89 1356 1365 O
disorder 90 98 1366 1374 O
of 99 101 1375 1377 O
bilirubin 102 111 1378 1387 O
metabolism 112 122 1388 1398 O
( 123 124 1399 1400 O
e.g. 124 128 1400 1404 O
, 128 129 1404 1405 O
Gilbert 130 137 1406 1413 B-chronic_disease
syndrome 138 146 1414 1422 I-chronic_disease
) 146 147 1422 1423 O
will 148 152 1424 1428 O
be 153 155 1429 1431 O
eligible 156 164 1432 1440 O
at 165 167 1441 1443 O
the 168 171 1444 1447 O
discretion 172 182 1448 1458 O
of 183 185 1459 1461 O
the 186 189 1462 1465 O
principal 190 199 1466 1475 O
investigator 200 212 1476 1488 O

Concomitant 0 11 1489 1500 B-treatment
treatment 12 21 1501 1510 I-treatment
with 22 26 1511 1515 O
other 27 32 1516 1521 O
anti 33 37 1522 1526 B-treatment
- 37 38 1526 1527 I-treatment
neoplastic 38 48 1527 1537 I-treatment
agents 49 55 1538 1544 I-treatment
( 56 57 1545 1546 O
hormonal 57 65 1546 1554 B-treatment
therapy 66 73 1555 1562 I-treatment
acceptable 74 84 1563 1573 O
) 84 85 1573 1574 O

Congestive 0 10 1575 1585 B-chronic_disease
heart 11 16 1586 1591 I-chronic_disease
failure 17 24 1592 1599 I-chronic_disease
( 25 26 1600 1601 I-chronic_disease
CHF 26 29 1601 1604 I-chronic_disease
) 29 30 1604 1605 I-chronic_disease
New 31 34 1606 1609 B-clinical_variable
York 35 39 1610 1614 I-clinical_variable
( 40 41 1615 1616 I-clinical_variable
NY 41 43 1616 1618 I-clinical_variable
) 43 44 1618 1619 I-clinical_variable
Heart 45 50 1620 1625 I-clinical_variable
Association 51 62 1626 1637 I-clinical_variable
class 63 68 1638 1643 I-clinical_variable
III 69 72 1644 1647 B-lower_bound
or 73 75 1648 1650 O
IV 76 78 1651 1653 B-upper_bound

Creatinine 0 10 1654 1664 B-clinical_variable
≤ 11 12 1665 1666 O
1.5 13 16 1667 1670 B-upper_bound
x 17 18 1671 1672 I-upper_bound
ULN 19 22 1673 1676 B-clinical_variable
or 23 25 1677 1679 O
calculated 26 36 1680 1690 B-clinical_variable
creatinine 37 47 1691 1701 I-clinical_variable
clearance 48 57 1702 1711 I-clinical_variable
( 58 59 1712 1713 I-clinical_variable
CrCl 59 63 1713 1717 I-clinical_variable
) 63 64 1717 1718 I-clinical_variable
> 65 66 1719 1720 O
60 67 69 1721 1723 B-lower_bound
mL 70 72 1724 1726 I-lower_bound
/ 72 73 1726 1727 I-lower_bound
min 73 76 1727 1730 I-lower_bound
using 77 82 1731 1736 O
the 83 86 1737 1740 O
Cockcroft 87 96 1741 1750 O
- 96 97 1750 1751 O
Gault 97 102 1751 1756 O
formula 103 110 1757 1764 O
less 111 115 1765 1769 O
than 116 120 1770 1774 O
eight 121 126 1775 1780 B-upper_bound
days 127 131 1781 1785 I-upper_bound
pior 132 136 1786 1790 I-upper_bound
to 137 139 1791 1793 O
start 140 145 1794 1799 O
of 146 148 1800 1802 O
treatment 149 158 1803 1812 B-treatment

Disease 0 7 1813 1820 O
site 8 12 1821 1825 O
/ 12 13 1825 1826 O
type 13 17 1826 1830 O
with 18 22 1831 1835 O
pathologic 23 33 1836 1846 O
confirmation 34 46 1847 1859 O
of 47 49 1860 1862 O
diagnosis 50 59 1863 1872 O
at 60 62 1873 1875 O
participating 63 76 1876 1889 O
cancer 77 83 1890 1896 B-cancer
site 84 88 1897 1901 O

Eastern 0 7 1902 1909 B-clinical_variable
Cooperative 8 19 1910 1921 I-clinical_variable
Oncology 20 28 1922 1930 I-clinical_variable
Group 29 34 1931 1936 I-clinical_variable
( 35 36 1937 1938 I-clinical_variable
ECOG 36 40 1938 1942 I-clinical_variable
) 40 41 1942 1943 I-clinical_variable
performance 42 53 1944 1955 I-clinical_variable
status 54 60 1956 1962 I-clinical_variable
: 60 61 1962 1963 O
0 62 63 1964 1965 B-lower_bound
, 63 64 1965 1966 O
1 65 66 1967 1968 O
, 66 67 1968 1969 O
or 68 70 1970 1972 O
2 71 72 1973 1974 B-upper_bound

Examples 0 8 1975 1983 O
of 9 11 1984 1986 O
the 12 15 1987 1990 O
latter 16 22 1991 1997 O
include 23 30 1998 2005 O
basal 31 36 2006 2011 B-cancer
or 37 39 2012 2014 O
squamous 40 48 2015 2023 B-cancer
cell 49 53 2024 2028 I-cancer
carcinoma 54 63 2029 2038 I-cancer
of 64 66 2039 2041 I-cancer
the 67 70 2042 2045 I-cancer
skin 71 75 2046 2050 I-cancer
, 75 76 2050 2051 O
in 77 79 2052 2054 B-cancer
- 79 80 2054 2055 I-cancer
situ 80 84 2055 2059 I-cancer
carcinoma 85 94 2060 2069 I-cancer
of 95 97 2070 2072 I-cancer
the 98 101 2073 2076 I-cancer
cervix 102 108 2077 2083 I-cancer
, 108 109 2083 2084 O
and 110 113 2085 2088 O
isolated 114 122 2089 2097 O
elevation 123 132 2098 2107 O
of 133 135 2108 2110 O
prostate 136 144 2111 2119 B-clinical_variable
- 144 145 2119 2120 I-clinical_variable
specific 145 153 2120 2128 I-clinical_variable
antigen 154 161 2129 2136 I-clinical_variable

Fertile 0 7 2137 2144 O
men 8 11 2145 2148 B-gender
must 12 16 2149 2153 O
agree 17 22 2154 2159 B-contraception_consent
to 23 25 2160 2162 I-contraception_consent
use 26 29 2163 2166 I-contraception_consent
an 30 32 2167 2169 I-contraception_consent
effective 33 42 2170 2179 I-contraception_consent
method 43 49 2180 2186 I-contraception_consent
of 50 52 2187 2189 I-contraception_consent
birth 53 58 2190 2195 I-contraception_consent
control 59 66 2196 2203 I-contraception_consent
during 67 73 2204 2210 O
the 74 77 2211 2214 O
study 78 83 2215 2220 O
and 84 87 2221 2224 O
for 88 91 2225 2228 O
up 92 94 2229 2231 O
to 95 97 2232 2234 O
3 98 99 2235 2236 B-upper_bound
months 100 106 2237 2243 I-upper_bound
after 107 112 2244 2249 I-upper_bound
the 113 116 2250 2253 O
last 117 121 2254 2258 O
dose 122 126 2259 2263 O
of 127 129 2264 2266 O
study 130 135 2267 2272 B-treatment
drug 136 140 2273 2277 I-treatment

For 0 3 2278 2281 O
this 4 8 2282 2286 O
reason 9 15 2287 2293 O
women 16 21 2294 2299 B-gender
of 22 24 2300 2302 O
child 25 30 2303 2308 O
- 30 31 2308 2309 O
bearing 31 38 2309 2316 O
potential 39 48 2317 2326 O
and 49 52 2327 2330 O
men 53 56 2331 2334 O
must 57 61 2335 2339 O
agree 62 67 2340 2345 B-contraception_consent
to 68 70 2346 2348 I-contraception_consent
use 71 74 2349 2352 I-contraception_consent
adequate 75 83 2353 2361 I-contraception_consent
contraception 84 97 2362 2375 I-contraception_consent
( 98 99 2376 2377 O
hormonal 99 107 2377 2385 B-contraception_consent
or 108 110 2386 2388 O
barrier 111 118 2389 2396 B-contraception_consent
method 119 125 2397 2403 I-contraception_consent
of 126 128 2404 2406 I-contraception_consent
birth 129 134 2407 2412 I-contraception_consent
control 135 142 2413 2420 I-contraception_consent
; 142 143 2420 2421 O
abstinence 144 154 2422 2432 B-contraception_consent
) 154 155 2432 2433 O
prior 156 161 2434 2439 O
to 162 164 2440 2442 O
study 165 170 2443 2448 O
entry 171 176 2449 2454 O
and 177 180 2455 2458 O
for 181 184 2459 2462 O
the 185 188 2463 2466 O
duration 189 197 2467 2475 O
of 198 200 2476 2478 O
study 201 206 2479 2484 O
participation 207 220 2485 2498 O

HIV 0 3 2499 2502 B-chronic_disease
- 3 4 2502 2503 O
positive 4 12 2503 2511 O
patients 13 21 2512 2520 O
on 22 24 2521 2523 O
combination 25 36 2524 2535 O
antiretroviral 37 51 2536 2550 B-treatment
therapy 52 59 2551 2558 I-treatment
are 60 63 2559 2562 O
ineligible 64 74 2563 2573 O
because 75 82 2574 2581 O
of 83 85 2582 2584 O
the 86 89 2585 2588 O
potential 90 99 2589 2598 O
for 100 103 2599 2602 O
pharmacokinetic 104 119 2603 2618 O
interactions 120 132 2619 2631 O
with 133 137 2632 2636 O
PLX3397 138 145 2637 2644 B-treatment

History 0 7 2645 2652 O
of 8 10 2653 2655 O
allergic 11 19 2656 2664 O
reactions 20 29 2665 2674 O
attributed 30 40 2675 2685 O
to 41 43 2686 2688 O
compounds 44 53 2689 2698 O
of 54 56 2699 2701 O
similar 57 64 2702 2709 O
chemical 65 73 2710 2718 O
or 74 76 2719 2721 O
biologic 77 85 2722 2730 O
composition 86 97 2731 2742 O
to 98 100 2743 2745 O
PLX3397 101 108 2746 2753 B-allergy_name
or 109 111 2754 2756 O
sirolimus 112 121 2757 2766 B-allergy_name

Major 0 5 2767 2772 B-treatment
surgical 6 14 2773 2781 I-treatment
procedure 15 24 2782 2791 I-treatment
or 25 27 2792 2794 O
significant 28 39 2795 2806 O
traumatic 40 49 2807 2816 B-chronic_disease
injury 50 56 2817 2823 I-chronic_disease
within 57 63 2824 2830 O
14 64 66 2831 2833 B-upper_bound
days 67 71 2834 2838 I-upper_bound
of 72 74 2839 2841 O
initiating 75 85 2842 2852 O
study 86 91 2853 2858 O
drug 92 96 2859 2863 O
or 97 99 2864 2866 O
anticipation 100 112 2867 2879 O
of 113 115 2880 2882 O
the 116 119 2883 2886 O
need 120 124 2887 2891 O
for 125 128 2892 2895 O
major 129 134 2896 2901 B-treatment
surgery 135 142 2902 2909 I-treatment
during 143 149 2910 2916 O
the 150 153 2917 2920 O
study 154 159 2921 2926 O

Men 0 3 2927 2930 B-gender
treated 4 11 2931 2938 O
or 12 14 2939 2941 O
enrolled 15 23 2942 2950 O
on 24 26 2951 2953 O
this 27 31 2954 2958 O
protocol 32 40 2959 2967 O
must 41 45 2968 2972 O
also 46 50 2973 2977 O
agree 51 56 2978 2983 B-contraception_consent
to 57 59 2984 2986 I-contraception_consent
use 60 63 2987 2990 I-contraception_consent
adequate 64 72 2991 2999 I-contraception_consent
contraception 73 86 3000 3013 I-contraception_consent
prior 87 92 3014 3019 O
to 93 95 3020 3022 O
the 96 99 3023 3026 O
study 100 105 3027 3032 O
, 105 106 3032 3033 O
for 107 110 3034 3037 O
the 111 114 3038 3041 O
duration 115 123 3042 3050 O
of 124 126 3051 3053 O
study 127 132 3054 3059 O
participation 133 146 3060 3073 O
, 146 147 3073 3074 O
and 148 151 3075 3078 O
3 152 153 3079 3080 B-upper_bound
months 154 160 3081 3087 I-upper_bound
after 161 166 3088 3093 O
completion 167 177 3094 3104 O
of 178 180 3105 3107 O
PLX3397 181 188 3108 3115 B-treatment
and 189 192 3116 3119 O
sirolimus 193 202 3120 3129 B-treatment
administration 203 217 3130 3144 I-treatment

Of 0 2 3145 3147 O
the 3 6 3148 3151 O
five 7 11 3152 3156 O
major 12 17 3157 3162 O
cytochrome 18 28 3163 3173 B-treatment
P450 29 33 3174 3178 I-treatment
( 34 35 3179 3180 I-treatment
CYP 35 38 3180 3183 I-treatment
) 38 39 3183 3184 I-treatment
isoforms 40 48 3185 3193 I-treatment
, 48 49 3193 3194 O
3A4 50 53 3195 3198 B-treatment
( 54 55 3199 3200 I-treatment
BFC 55 58 3200 3203 I-treatment
) 58 59 3203 3204 I-treatment
may 60 63 3205 3208 O
be 64 66 3209 3211 O
involved 67 75 3212 3220 O
in 76 78 3221 3223 O
Phase 79 84 3224 3229 O
I 85 86 3230 3231 O
metabolism 87 97 3232 3242 O
of 98 100 3243 3245 O
PLX3397 101 108 3246 3253 B-treatment
, 108 109 3253 3254 O
with 110 114 3255 3259 O
possibly 115 123 3260 3268 O
CYP1A2 124 130 3269 3275 B-treatment
playing 131 138 3276 3283 O
a 139 140 3284 3285 O
minor 141 146 3286 3291 O
role 147 151 3292 3296 O

Patients 0 8 3297 3305 O
should 9 15 3306 3312 O
be 16 18 3313 3315 O
monitored 19 28 3316 3325 O
for 29 32 3326 3329 O
supratherapeutic 33 49 3330 3346 O
toxic 50 55 3347 3352 O
levels 56 62 3353 3359 O
of 63 65 3360 3362 O
sirolimus 66 75 3363 3372 B-treatment
and 76 79 3373 3376 O
PLX3397 80 87 3377 3384 B-treatment

Patients 0 8 3385 3393 O
who 9 12 3394 3397 O
are 13 16 3398 3401 O
receiving 17 26 3402 3411 O
any 27 30 3412 3415 O
other 31 36 3416 3421 O
investigational 37 52 3422 3437 B-treatment
agents 53 59 3438 3444 I-treatment
concurrently 60 72 3445 3457 O

Patients 0 8 3458 3466 O
who 9 12 3467 3470 O
have 13 17 3471 3475 O
had 18 21 3476 3479 O
chemotherapy 22 34 3480 3492 B-treatment
or 35 37 3493 3495 O
radiotherapy 38 50 3496 3508 B-treatment
within 51 57 3509 3515 O
4 58 59 3516 3517 O
weeks 60 65 3518 3523 O
( 66 67 3524 3525 O
6 67 68 3525 3526 B-lower_bound
weeks 69 74 3527 3532 I-lower_bound
for 75 78 3533 3536 O
nitrosoureas 79 91 3537 3549 B-treatment
or 92 94 3550 3552 O
mitomycin 95 104 3553 3562 B-treatment
C 105 106 3563 3564 I-treatment
) 106 107 3564 3565 O
prior 108 113 3566 3571 O
to 114 116 3572 3574 O
entering 117 125 3575 3583 O
the 126 129 3584 3587 O
study 130 135 3588 3593 O
or 136 138 3594 3596 O
those 139 144 3597 3602 O
who 145 148 3603 3606 O
have 149 153 3607 3611 O
not 154 157 3612 3615 O
recovered 158 167 3616 3625 O
from 168 172 3626 3630 O
adverse 173 180 3631 3638 O
events 181 187 3639 3645 O
due 188 191 3646 3649 O
to 192 194 3650 3652 O
agents 195 201 3653 3659 O
administered 202 214 3660 3672 O
more 215 219 3673 3677 O
than 220 224 3678 3682 O
4 225 226 3683 3684 O
weeks 227 232 3685 3690 O
earlier 233 240 3691 3698 O

Patients 0 8 3699 3707 O
with 9 13 3708 3712 O
symptomatic 14 25 3713 3724 B-cancer
brain 26 31 3725 3730 I-cancer
metastases 32 42 3731 3741 I-cancer

Phase 0 5 3742 3747 O
1 6 7 3748 3749 O
: 7 8 3749 3750 O
Advanced 9 17 3751 3759 O
, 17 18 3759 3760 O
unresectable 19 31 3761 3773 O
sarcoma 32 39 3774 3781 B-cancer
( 40 41 3782 3783 O
any 41 44 3783 3786 O
subtype 45 52 3787 3794 O
) 52 53 3794 3795 O

Phase 0 5 3796 3801 O
1 6 7 3802 3803 O
: 7 8 3803 3804 O
Progressed 9 19 3805 3815 O
on 20 22 3816 3818 O
standard 23 31 3819 3827 O
of 32 34 3828 3830 O
care 35 39 3831 3835 O
therapy 40 47 3836 3843 B-treatment
with 48 52 3844 3848 O
up 53 55 3849 3851 O
to 56 58 3852 3854 O
three 59 64 3855 3860 B-upper_bound
prior 65 70 3861 3866 I-upper_bound
treatments 71 81 3867 3877 O

Phase 0 5 3878 3883 O
2 6 7 3884 3885 O
: 7 8 3885 3886 O
Advanced 9 17 3887 3895 O
, 17 18 3895 3896 O
unresectable 19 31 3897 3909 O
malignant 32 41 3910 3919 B-cancer
peripheral 42 52 3920 3930 I-cancer
nerve 53 58 3931 3936 I-cancer
sheath 59 65 3937 3943 I-cancer
tumors 66 72 3944 3950 I-cancer
( 73 74 3951 3952 I-cancer
MPNSTs 74 80 3952 3958 I-cancer
) 80 81 3958 3959 I-cancer

Phase 0 5 3960 3965 O
2 6 7 3966 3967 O
: 7 8 3967 3968 O
MPNST 9 14 3969 3974 B-cancer
with 15 19 3975 3979 O
0 20 21 3980 3981 B-lower_bound
- 21 22 3981 3982 O
3 22 23 3982 3983 B-upper_bound
prior 24 29 3984 3989 B-treatment
systemic 30 38 3990 3998 I-treatment
treatments 39 49 3999 4009 I-treatment
( 50 51 4010 4011 O
no 51 53 4011 4013 O
prior 54 59 4014 4019 B-treatment
radiotherapy 60 72 4020 4032 I-treatment
is 73 75 4033 4035 O
necessary 76 85 4036 4045 O
) 85 86 4045 4046 O

Pregnant 0 8 4047 4055 B-pregnancy
women 9 14 4056 4061 B-gender
are 15 18 4062 4065 O
excluded 19 27 4066 4074 O
from 28 32 4075 4079 O
this 33 37 4080 4084 O
study 38 43 4085 4090 O
because 44 51 4091 4098 O
PLX3397 52 59 4099 4106 B-treatment
and 60 63 4107 4110 O
sirolimus 64 73 4111 4120 B-treatment
are 74 77 4121 4124 O
agents 78 84 4125 4131 O
with 85 89 4132 4136 O
the 90 93 4137 4140 O
potential 94 103 4141 4150 O
for 104 107 4151 4154 O
teratogenic 108 119 4155 4166 B-treatment
or 120 122 4167 4169 O
abortifacient 123 136 4170 4183 B-treatment
effects 137 144 4184 4191 O

Previous 0 8 4192 4200 B-treatment
radiotherapy 9 21 4201 4213 I-treatment
to 22 24 4214 4216 O
25 25 27 4217 4219 B-lower_bound
% 27 28 4219 4220 I-lower_bound
or 29 31 4221 4223 O
more 32 36 4224 4228 O
of 37 39 4229 4231 O
the 40 43 4232 4235 O
bone 44 48 4236 4240 B-treatment
marrow 49 55 4241 4247 I-treatment
and/or 56 62 4248 4254 O
radiation 63 72 4255 4264 B-treatment
therapy 73 80 4265 4272 I-treatment
within 81 87 4273 4279 O
28 88 90 4280 4282 B-upper_bound
days 91 95 4283 4287 I-upper_bound
prior 96 101 4288 4293 I-upper_bound
to 102 104 4294 4296 O
study 105 110 4297 4302 O
entry 111 116 4303 4308 O

Prior 0 5 4309 4314 B-treatment
treatment 6 15 4315 4324 I-treatment
- 15 16 4324 4325 I-treatment
related 16 23 4325 4332 I-treatment
Adverse 24 31 4333 4340 I-treatment
Events 32 38 4341 4347 I-treatment
must 39 43 4348 4352 O
be 44 46 4353 4355 O
≤ 47 48 4356 4357 O
grade 49 54 4358 4363 B-upper_bound
1 55 56 4364 4365 I-upper_bound
( 57 58 4366 4367 O
CTCAE 58 63 4367 4372 O
v4.0 64 68 4373 4377 O
) 68 69 4377 4378 O
, 69 70 4378 4379 O
except 71 77 4380 4386 O
alopecia 78 86 4387 4395 B-chronic_disease
, 86 87 4395 4396 O
at 88 90 4397 4399 O
time 91 95 4400 4404 O
of 96 98 4405 4407 O
initiating 99 109 4408 4418 O
study 110 115 4419 4424 O
drug 116 120 4425 4429 O

Should 0 6 4430 4436 O
a 7 8 4437 4438 O
woman 9 14 4439 4444 B-gender
become 15 21 4445 4451 B-pregnancy
pregnant 22 30 4452 4460 I-pregnancy
or 31 33 4461 4463 O
suspect 34 41 4464 4471 O
she 42 45 4472 4475 O
is 46 48 4476 4478 O
pregnant 49 57 4479 4487 O
while 58 63 4488 4493 O
she 64 67 4494 4497 O
or 68 70 4498 4500 O
her 71 74 4501 4504 O
partner 75 82 4505 4512 O
is 83 85 4513 4515 O
participating 86 99 4516 4529 O
in 100 102 4530 4532 O
this 103 107 4533 4537 O
study 108 113 4538 4543 O
, 113 114 4543 4544 O
she 115 118 4545 4548 O
should 119 125 4549 4555 O
inform 126 132 4556 4562 O
her 133 136 4563 4566 O
treating 137 145 4567 4575 O
physician 146 155 4576 4585 O
immediately 156 167 4586 4597 O

Sirolimus 0 9 4598 4607 B-treatment
undergoes 10 19 4608 4617 O
extensive 20 29 4618 4627 B-treatment
hepatic 30 37 4628 4635 I-treatment
and 38 41 4636 4639 I-treatment
intestinal 42 52 4640 4650 I-treatment
metabolism 53 63 4651 4661 I-treatment
via 64 67 4662 4665 I-treatment
CYP3A4 68 74 4666 4672 I-treatment
and 75 78 4673 4676 I-treatment
CYP3A5 79 85 4677 4683 I-treatment
, 85 86 4683 4684 I-treatment
as 87 89 4685 4687 I-treatment
well 90 94 4688 4692 I-treatment
as 95 97 4693 4695 I-treatment
excretion 98 107 4696 4705 I-treatment
by 108 110 4706 4708 I-treatment
P 111 112 4709 4710 I-treatment
- 112 113 4710 4711 I-treatment
glycoprotein 113 125 4711 4723 I-treatment

Some 0 4 4724 4728 O
common 5 11 4729 4735 O
examples 12 20 4736 4744 O
include 21 28 4745 4752 O
inhibitors 29 39 4753 4763 B-treatment
such 40 44 4764 4768 O
as 45 47 4769 4771 O
erythromycin 48 60 4772 4784 B-treatment
, 60 61 4784 4785 O
fluoxetine 62 72 4786 4796 B-treatment
, 72 73 4796 4797 O
gemfibrozil 74 85 4798 4809 B-treatment
, 85 86 4809 4810 O
and 87 90 4811 4814 O
inducers 91 99 4815 4823 B-treatment
such 100 104 4824 4828 O
as 105 107 4829 4831 O
rifampicin 108 118 4832 4842 B-treatment
, 118 119 4842 4843 O
carbamazepine 120 133 4844 4857 B-treatment
, 133 134 4857 4858 O
phenytoin 135 144 4859 4868 B-treatment
, 144 145 4868 4869 O
efavirenz 146 155 4870 4879 B-treatment
, 155 156 4879 4880 O
and 157 160 4881 4884 O
nevirapine 161 171 4885 4895 B-treatment

Strong 0 6 4896 4902 O
CYP3A 7 12 4903 4908 B-treatment
inhibitors 13 23 4909 4919 I-treatment
such 24 28 4920 4924 O
as 29 31 4925 4927 O
ketoconazole 32 44 4928 4940 B-treatment
or 45 47 4941 4943 O
grapefruit 48 58 4944 4954 B-treatment
juice 59 64 4955 4960 I-treatment
are 65 68 4961 4964 O
not 69 72 4965 4968 O
permitted 73 82 4969 4978 O

Subjects 0 8 4979 4987 O
with 9 13 4988 4992 O
a 14 15 4993 4994 O
completely 16 26 4995 5005 O
treated 27 34 5006 5013 O
prior 35 40 5014 5019 O
malignancy 41 51 5020 5030 B-cancer
and 52 55 5031 5034 O
no 56 58 5035 5037 O
evidence 59 67 5038 5046 O
of 68 70 5047 5049 O
disease 71 78 5050 5057 O
for 79 82 5058 5061 O
≥ 83 84 5062 5063 O
2 85 86 5064 5065 B-lower_bound
years 87 92 5066 5071 I-lower_bound
are 93 96 5072 5075 O
eligible 97 105 5076 5084 O

These 0 5 5085 5090 O
include 6 13 5091 5098 O
anticonvulsants 14 29 5099 5114 B-treatment
, 29 30 5114 5115 O
mycin 31 36 5116 5121 B-treatment
antimicrobials 37 51 5122 5136 I-treatment
, 51 52 5136 5137 O
and 53 56 5138 5141 O
antiretrovirals 57 72 5142 5157 B-treatment

Uncontrolled 0 12 5158 5170 O
intercurrent 13 25 5171 5183 O
illness 26 33 5184 5191 O
including 34 43 5192 5201 O
, 43 44 5201 5202 O
but 45 48 5203 5206 O
not 49 52 5207 5210 O
limited 53 60 5211 5218 O
to 61 63 5219 5221 O
, 63 64 5221 5222 O
ongoing 65 72 5223 5230 O
or 73 75 5231 5233 O
active 76 82 5234 5240 B-chronic_disease
infection 83 92 5241 5250 I-chronic_disease
, 92 93 5250 5251 O
active 94 100 5252 5258 B-chronic_disease
liver 101 106 5259 5264 I-chronic_disease
disease 107 114 5265 5272 I-chronic_disease
, 114 115 5272 5273 O
symptomatic 116 127 5274 5285 O
congestive 128 138 5286 5296 B-chronic_disease
heart 139 144 5297 5302 I-chronic_disease
failure 145 152 5303 5310 I-chronic_disease
, 152 153 5310 5311 O
unstable 154 162 5312 5320 B-chronic_disease
angina 163 169 5321 5327 I-chronic_disease
pectoris 170 178 5328 5336 I-chronic_disease
, 178 179 5336 5337 O
cardiac 180 187 5338 5345 B-chronic_disease
arrhythmia 188 198 5346 5356 I-chronic_disease
, 198 199 5356 5357 O
or 200 202 5358 5360 O
psychiatric 203 214 5361 5372 B-chronic_disease
illness 215 222 5373 5380 I-chronic_disease
/ 222 223 5380 5381 I-chronic_disease
social 223 229 5381 5387 I-chronic_disease
situations 230 240 5388 5398 I-chronic_disease
that 241 245 5399 5403 O
would 246 251 5404 5409 O
limit 252 257 5410 5415 O
compliance 258 268 5416 5426 O
with 269 273 5427 5431 O
study 274 279 5432 5437 O
requirements 280 292 5438 5450 O

Until 0 5 5451 5456 O
information 6 17 5457 5468 O
regarding 18 27 5469 5478 O
exposure 28 36 5479 5487 O
toxicity 37 45 5488 5496 O
and 46 49 5497 5500 O
exposure 50 58 5501 5509 O
- 58 59 5509 5510 O
response 59 67 5510 5518 O
relationships 68 81 5519 5532 O
are 82 85 5533 5536 O
available 86 95 5537 5546 O
with 96 100 5547 5551 O
PLX3397 101 108 5552 5559 B-treatment
, 108 109 5559 5560 O
concomitant 110 121 5561 5572 O
strong 122 128 5573 5579 B-treatment
CYP3A4 129 135 5580 5586 I-treatment
inhibitors 136 146 5587 5597 I-treatment
and 147 150 5598 5601 I-treatment
inducers 151 159 5602 5610 I-treatment
are 160 163 5611 5614 O
not 164 167 5615 5618 O
permitted 168 177 5619 5628 O
in 178 180 5629 5631 O
the 181 184 5632 5635 O
event 185 190 5636 5641 O
they 191 195 5642 5646 O
alter 196 201 5647 5652 O
the 202 205 5653 5656 O
systemic 206 214 5657 5665 O
exposure 215 223 5666 5674 O
to 224 226 5675 5677 O
PLX3397 227 234 5678 5685 O
( 235 236 5686 5687 O
see 236 239 5687 5690 O
Attachment 240 250 5691 5701 O
1 251 252 5702 5703 O
for 253 256 5704 5707 O
a 257 258 5708 5709 O
list 259 263 5710 5714 O
of 264 266 5715 5717 O
common 267 273 5718 5724 O
CYP3A4 274 280 5725 5731 O
inhibitors 281 291 5732 5742 O
and 292 295 5743 5746 O
inducers 296 304 5747 5755 O
) 304 305 5755 5756 O

Women 0 5 5757 5762 B-gender
of 6 8 5763 5765 O
child 9 14 5766 5771 O
- 14 15 5771 5772 O
bearing 15 22 5772 5779 O
potential 23 32 5780 5789 O
must 33 37 5790 5794 O
have 38 42 5795 5799 O
a 43 44 5800 5801 O
negative 45 53 5802 5810 B-pregnancy
serum 54 59 5811 5816 I-pregnancy
pregnancy 60 69 5817 5826 I-pregnancy
test 70 74 5827 5831 O
at 75 77 5832 5834 O
screening 78 87 5835 5844 O
and 88 91 5845 5848 O
must 92 96 5849 5853 O
agree 97 102 5854 5859 B-contraception_consent
to 103 105 5860 5862 I-contraception_consent
use 106 109 5863 5866 I-contraception_consent
an 110 112 5867 5869 I-contraception_consent
effective 113 122 5870 5879 I-contraception_consent
form 123 127 5880 5884 I-contraception_consent
of 128 130 5885 5887 I-contraception_consent
contraception 131 144 5888 5901 I-contraception_consent
from 145 149 5902 5906 O
the 150 153 5907 5910 O
time 154 158 5911 5915 O
of 159 161 5916 5918 O
the 162 165 5919 5922 O
negative 166 174 5923 5931 B-pregnancy
pregnancy 175 184 5932 5941 I-pregnancy
test 185 189 5942 5946 O
and 190 193 5947 5950 O
for 194 197 5951 5954 O
a 198 199 5955 5956 O
minimum 200 207 5957 5964 O
of 208 210 5965 5967 O
3 211 212 5968 5969 B-lower_bound
months 213 219 5970 5976 I-lower_bound
after 220 225 5977 5982 I-lower_bound
the 226 229 5983 5986 O
last 230 234 5987 5991 O
dose 235 239 5992 5996 O
of 240 242 5997 5999 O
study 243 248 6000 6005 B-treatment
drug 249 253 6006 6010 I-treatment

Women 0 5 6011 6016 B-gender
of 6 8 6017 6019 O
non 9 12 6020 6023 O
- 12 13 6023 6024 O
child 13 18 6024 6029 O
- 18 19 6029 6030 O
bearing 19 26 6030 6037 O
potential 27 36 6038 6047 O
must 37 41 6048 6052 O
have 42 46 6053 6057 O
been 47 51 6058 6062 O
postmenopausal 52 66 6063 6077 B-clinical_variable
for 67 70 6078 6081 O
≥ 71 72 6082 6083 O
1 73 74 6084 6085 B-lower_bound
year 75 79 6086 6090 I-lower_bound
or 80 82 6091 6093 O
surgically 83 93 6094 6104 O
sterile 94 101 6105 6112 O

bilirubin 0 9 6113 6122 B-clinical_variable
≤ 10 11 6123 6124 O
1.5 12 15 6125 6128 B-upper_bound
x 16 17 6129 6130 I-upper_bound
ULN 18 21 6131 6134 I-upper_bound
, 21 22 6134 6135 O
albumin 23 30 6136 6143 B-clinical_variable
≥ 31 32 6144 6145 O
3.0g 33 37 6146 6150 B-lower_bound
/ 37 38 6150 6151 I-lower_bound
dL 38 40 6151 6153 I-lower_bound

patients 0 8 6154 6162 O
with 9 13 6163 6167 O
chronic 14 21 6168 6175 B-chronic_disease
or 22 24 6176 6178 I-chronic_disease
acute 25 30 6179 6184 I-chronic_disease
hepatitis 31 40 6185 6194 I-chronic_disease
C 41 42 6195 6196 I-chronic_disease
virus 43 48 6197 6202 I-chronic_disease
( 49 50 6203 6204 I-chronic_disease
HCV 50 53 6204 6207 I-chronic_disease
) 53 54 6207 6208 I-chronic_disease
or 55 57 6209 6211 O
hepatitis 58 67 6212 6221 B-chronic_disease
B 68 69 6222 6223 I-chronic_disease
virus 70 75 6224 6229 I-chronic_disease
( 76 77 6230 6231 I-chronic_disease
HBV 77 80 6231 6234 I-chronic_disease
) 80 81 6234 6235 I-chronic_disease
infection 82 91 6236 6245 I-chronic_disease
are 92 95 6246 6249 O
also 96 100 6250 6254 O
ineligible 101 111 6255 6265 O

these 0 5 6266 6271 O
patients 6 14 6272 6280 O
are 15 18 6281 6284 O
at 19 21 6285 6287 O
increased 22 31 6288 6297 O
risk 32 36 6298 6302 O
of 37 39 6303 6305 O
lethal 40 46 6306 6312 O
infections 47 57 6313 6323 O
when 58 62 6324 6328 O
treated 63 70 6329 6336 O
with 71 75 6337 6341 O
marrow 76 82 6342 6348 B-treatment
suppressive 83 94 6349 6360 I-treatment
therapy 95 102 6361 6368 I-treatment

unstable 0 8 6369 6377 O
coronary 9 17 6378 6386 B-chronic_disease
artery 18 24 6387 6393 I-chronic_disease
disease 25 32 6394 6401 I-chronic_disease
( 33 34 6402 6403 O
myocardial 34 44 6403 6413 B-chronic_disease
infarction 45 55 6414 6424 I-chronic_disease
( 56 57 6425 6426 I-chronic_disease
MI 57 59 6426 6428 I-chronic_disease
) 59 60 6428 6429 I-chronic_disease
more 61 65 6430 6434 O
than 66 70 6435 6439 O
6 71 72 6440 6441 B-lower_bound
months 73 79 6442 6448 I-lower_bound
prior 80 85 6449 6454 I-lower_bound
to 86 88 6455 6457 O
study 89 94 6458 6463 O
entry 95 100 6464 6469 O
is 101 103 6470 6472 O
permitted 104 113 6473 6482 O
) 113 114 6482 6483 O
; 114 115 6483 6484 O
or 116 118 6485 6487 O
serious 119 126 6488 6495 O
cardiac 127 134 6496 6503 B-chronic_disease
arrhythmia 135 145 6504 6514 I-chronic_disease

